Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has reported E.P.S. of $2.33 for its third fiscal quarter (ending September 30) versus $-0.31 for the same period a year ago. Relative to the consensus estimate of $4.93, this was a shortfall of $-2.60. For the latest four quarters through September 30, E.P.S. were $1.23 compared to $-0.30 a year ago.
Recent Price Action
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock suffered a large decline of -4.1% on 11/8/23. The stock closed at $128.24. The stock has performed in line with the market over the last nine months and has risen 1.0% during the last week.
Current PriceTarget Research Rating
JAZZ is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Jazz Pharmaceuticals plc has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Jazz Pharmaceuticals plc has a neutral Power Rating of 50 but a good Appreciation Score of 77, resulting in the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment